Workflow
亚健康医疗服务
icon
Search documents
国证国际:维持美丽田园医疗健康(02373)“买入”评级 目标价45港元
Zhi Tong Cai Jing· 2025-09-19 01:46
Group 1 - The core viewpoint of the report is that Meili Tianyuan Medical Health (02373) is expected to maintain strong financial performance, with projected revenues of 3.05 billion, 3.41 billion, and 3.76 billion RMB for 2025-2027, and net profits of 320 million, 380 million, and 440 million RMB respectively [1] - The company achieved record high adjusted net profit in H1 2025, with revenues, net profit, and adjusted net profit reaching 1.46 billion, 170 million, and 190 million RMB respectively, representing year-on-year growth of 28%, 36%, and 38% [1] - The operating cash flow for H1 2025 was 410 million RMB, an increase of 84% year-on-year, with cash and cash equivalents amounting to 2 billion RMB, up 28% [1] Group 2 - The beauty and health services segment generated 810 million RMB in revenue, a year-on-year increase of 30%, while the medical beauty services segment achieved 500 million RMB, growing by 13% [1] - The sub-health medical services segment saw a remarkable revenue increase of 108%, reaching 150 million RMB, with the number of outpatient clinics expanding to 11 [1] - The Women's Health Center, a key part of the sub-health medical business, reported a revenue growth of 173% in H1 2025 [1] Group 3 - The company increased its stake in Nairu to 90%, enhancing profitability, with Nairu's revenue reaching 280 million RMB in H1 2025 and adjusted net profit margin rising from 6.5% to 10.4% [2] - Nairu, recognized as the "First Brand of Intelligent Beauty and Health" by Frost & Sullivan, is implementing an AI-driven transformation project called "Intelligent Beauty and Health 2.0 System" [2] Group 4 - The company has announced a "Capital Market Value Enhancement Plan" aimed at increasing shareholder returns, optimizing capital structure, and promoting sustainable development, with a total of 300 million RMB in dividends declared over the past three years [3] - The first dividend payment from the shareholder return plan is scheduled to be distributed by September 26, 2025, at a rate of 0.52 HKD per share [3]
美丽田园医疗健康(02373.HK):业绩高增 “内生+外延”战略持续显效
Ge Long Hui· 2025-09-04 04:09
Core Insights - The company reported a revenue of 1.46 billion yuan for the first half of 2025, representing a year-on-year increase of 28.2%, and a net profit of 170 million yuan, up 35.5% year-on-year [1] - The company's three main business segments showed strong growth, with the sub-health medical service revenue doubling [1] Revenue Breakdown - Beauty and health services generated 810 million yuan, a year-on-year increase of 29.6%, accounting for 55.2% of total revenue, driven by improved same-store sales and the acquisition of the smart beauty brand Nairui [1] - Medical beauty services achieved 500 million yuan in revenue, up 13.0% year-on-year, representing 34.2% of total revenue, supported by the execution of the "internal growth + external acquisition" strategy [1] - Sub-health medical services reached 150 million yuan, a significant increase of 107.8% year-on-year, making up 10.6% of total revenue, attributed to the strategy attracting members and refined operations [1] Profitability Metrics - The gross margin for the first half of 2025 was 49.3%, an increase of 2.3 percentage points year-on-year [2] - The net profit margin stood at 11.70%, reflecting a year-on-year increase of 0.62 percentage points [2] - The company maintained a stable expense ratio, with sales, management, and R&D expense ratios at 17.19%, 16.22%, and 1.44%, respectively [2] Strategic Initiatives - The company emphasized its "internal growth + external acquisition" strategy, with the acquisition of Nairui, the second-largest brand in China's beauty industry, expected to be completed by July 2024 [2] - Nairui contributed 277 million yuan in revenue during the first half of 2025, with an adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [2] - The company plans to enhance Nairui's core advantages and implement its first AI digital transformation project, the "Smart Beauty 2.0 System" [2] Membership Growth - The company reported a 47.8% year-on-year increase in customer traffic to 920,000 visits at direct stores, and active membership grew by 46.5% to 120,000 [3] - Approximately 20% of beauty and health service members upgraded to medical beauty or sub-health services, driving higher-value business penetration [3] Investment Outlook - The company is expected to achieve net profits of 330 million yuan, 380 million yuan, and 430 million yuan for 2025-2027, representing year-on-year growth of 43.9%, 17.0%, and 12.2% respectively [3] - The current stock price corresponds to a price-to-earnings ratio of 23X, 20X, and 18X for 2025-2027 [3]
美丽田园医疗健康(02373):动态点评:收入利润再创新高,亚健康医疗增速亮眼
Guohai Securities· 2025-09-03 13:07
Investment Rating - The report maintains a "Buy" rating for the company [1][8]. Core Insights - The company achieved record high revenue and profit, driven by significant growth in its sub-healthcare segment [5]. - The company's revenue for H1 2025 reached 1.459 billion RMB, a year-on-year increase of 28.2%, with a net profit of 171 million RMB, up 35.5% year-on-year [5]. - The "internal + external" strategy is expected to continue driving growth, with projected revenues of 3 billion RMB in 2025, 3.4 billion RMB in 2026, and 3.7 billion RMB in 2027 [5]. Financial Performance - The company reported a gross margin of 49.3% for H1 2025, an increase of 2.3 percentage points year-on-year [5]. - The operating cash flow for H1 2025 was 410 million RMB, reflecting an 84.4% increase year-on-year [5]. - As of June 30, 2025, the company had cash and cash equivalents totaling 2 billion RMB, a 27.5% increase year-on-year [5]. Business Segments - The beauty and wellness services segment generated revenue of 807 million RMB in H1 2025, a year-on-year increase of 29.6% [5]. - The medical beauty segment reported revenue of 499 million RMB, up 13.0% year-on-year, driven by increased patient visits [5]. - The sub-healthcare services segment saw remarkable growth, with revenue reaching 154 million RMB, a 107.8% increase year-on-year [5]. Membership Growth - The company experienced a 46.5% year-on-year increase in active members, reaching 120,000 members [5]. - The number of visitors to direct-operated stores exceeded 920,000 in H1 2025, representing a 47.8% increase year-on-year [5]. Future Projections - The company forecasts revenue growth of 18% in 2025, followed by 10% in 2026 and 9% in 2027 [5]. - The projected net profit for 2025 is 300 million RMB, with expected growth rates of 34% in 2025, 15% in 2026, and 15% in 2027 [5].
美丽田园医疗健康(02373):业绩高增,“内生+外延”战略持续显效
Minsheng Securities· 2025-09-02 05:32
Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4]. Core Insights - The company achieved significant growth in the first half of 2025, with revenue reaching 1.46 billion RMB, a year-on-year increase of 28.2%, and net profit of 170 million RMB, up 35.5% [1]. - The "internal growth + external acquisition" strategy has proven effective, particularly with the acquisition of the brand Nairui, which contributed 277 million RMB in revenue and improved its net profit margin from 6.5% to 10.4% [3]. - The company reported a gross margin of 49.3%, an increase of 2.3 percentage points year-on-year, and a net profit margin of 11.70%, up 0.62 percentage points [3]. Revenue Breakdown - The revenue from beauty and wellness services was 810 million RMB, a 29.6% increase, accounting for 55.2% of total revenue. Direct store income was 740 million RMB, up 31.0% [2]. - Medical beauty services generated 500 million RMB, a 13.0% increase, representing 34.2% of total revenue [2]. - The revenue from sub-health medical services doubled to 150 million RMB, a 107.8% increase, making up 10.6% of total revenue [2]. Membership Growth - The company reported a 47.8% increase in direct store customer traffic, reaching 920,000 visits, and active membership grew by 46.5% to 120,000 [4]. - Approximately 20% of beauty and wellness service members upgraded to medical beauty or sub-health services, enhancing the penetration of high-value business [4]. Financial Forecast - The company is projected to achieve net profits of 330 million RMB, 380 million RMB, and 430 million RMB for 2025, 2026, and 2027, respectively, with growth rates of 43.9%, 17.0%, and 12.2% [4][5]. - The current stock price corresponds to a price-to-earnings ratio (P/E) of 23X for 2025, 20X for 2026, and 18X for 2027 [4][5].
美丽田园医疗健康(02373.HK):1H经调净利同增38% 外延整合提效顺利推进
Ge Long Hui· 2025-08-30 04:01
Core Viewpoint - The company reported strong performance in 1H25, exceeding previous forecasts and expectations, driven by scale effects and operational efficiency improvements [1][2]. Financial Performance - Revenue for 1H25 reached 1.46 billion yuan, a year-on-year increase of 28.2% - Net profit attributable to shareholders was 160 million yuan, up 34.9% - Adjusted net profit was 190 million yuan, reflecting a 37.8% increase [1] - Gross margin improved by 2.4 percentage points to 49.3%, attributed to scale effects reducing procurement costs and diluting fixed costs [2] - Adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [2] Business Segments - Beauty and health services generated 810 million yuan in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 visits [1] - Medical beauty services revenue was 500 million yuan, a 13.0% increase, with active membership rising 27.6% to 24,000 [1] - Sub-health medical services saw revenue growth of 107.8% to 150 million yuan, with active members increasing 93.4% to 7,014 [1] Growth Strategy - The company is expanding its store network, adding 69 direct/franchise beauty and health service stores, 3 medical beauty stores, and 2 sub-health stores in 1H25 [1] - The company is focusing on enhancing operational efficiency and exploring acquisition opportunities to increase market share [3] - Recent changes in shareholder structure, including the entry of quality medical capital, are expected to support long-term growth [3] Valuation and Outlook - The company maintains its profit forecasts for 2025-2026, with current stock price corresponding to 25/21x P/E for those years [3] - Target price has been raised by 8% to 40 HKD, indicating a 21% upside potential based on the company's strong business model and growth opportunities [3]
美丽田园中期营收增长背后:女性悦己文化正重塑消费医疗赛道
Guan Cha Zhe Wang· 2025-08-28 12:32
Core Insights - The company reported a revenue of 1.46 billion RMB for the first half of 2025, representing a year-on-year growth of 28.2% [1][2] - The growth is attributed to structural changes in the Chinese consumer healthcare market, with emotional value becoming a key factor in consumer decision-making [1][6] - The company's "Double Beauty + Double Health" business model has shown strong adaptability, with a significant increase in demand for health services among female consumers [1][4] Financial Performance - The net profit for the first half of 2025 reached 170 million RMB, up 35.5% year-on-year, with an adjusted net profit margin of 13.1%, a historical high [2][4] - Cash and cash-equivalent assets amounted to 2 billion RMB, reflecting a 27.5% increase, while operating cash flow surged by 84.4% to 410 million RMB [2][4] - The gross profit for the period was 720 million RMB, a 34.7% increase, with a gross margin of 49.3%, up 2.3 percentage points [4][5] Business Segments - The beauty and health services segment generated 810 million RMB in revenue, a 29.6% increase, with a gross margin of 42.1% [4][5] - Medical beauty services revenue rose to 500 million RMB, a 13.0% increase, with a gross margin of 56.9% [5] - The sub-health medical services brand, Yan Yuan Medical, saw revenue soar by 107.8% to 150 million RMB, marking its first time exceeding 10% of total revenue [5][7] Consumer Trends - Emotional value is increasingly influencing the consumption decisions of younger generations, with the emotional economy projected to reach 2.3 trillion RMB by 2025 [1][6] - The target demographic includes women in high-tier cities, who are increasingly focused on self-care and emotional well-being [6][7] - The average spending per visit for members was 1,086 RMB, with high-end beauty services averaging 1,166 RMB per visit, indicating strong consumer willingness to invest in self-care [6][7]
中金:维持美丽田园医疗健康跑赢行业评级 上调目标价至40港元
Zhi Tong Cai Jing· 2025-08-28 03:28
Core Viewpoint - The company maintains its profit forecast for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on its strong business model and growth opportunities [1] Financial Performance - The company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%, and a net profit attributable to shareholders of RMB 160 million, up 34.9% [2] - Adjusted net profit reached RMB 190 million, reflecting a 37.8% year-on-year growth, exceeding previous forecasts due to scale effects and operational efficiency improvements [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic rising 48.6% to 850,000 visits [3] - Medical beauty services achieved RMB 500 million in revenue, up 13.0%, with active membership increasing 27.6% to 24,000 [3] - Sub-health medical services saw a remarkable revenue growth of 107.8% to RMB 150 million, with active members increasing 93.4% to 7,014 [3] Margin and Efficiency - The company's gross margin improved by 2.4 percentage points to 49.3% in 1H25, driven by scale effects and the inclusion of higher-margin businesses [4] - The adjusted net profit margin reached a historical high of 13.1%, with a year-on-year increase of 0.9 percentage points [4] Growth Strategy - The company is focused on enhancing operational efficiency and increasing service penetration through digital marketing [4] - It is also exploring acquisition opportunities to boost market share, with recent shareholder structure optimization expected to support long-term growth [4]
中金:维持美丽田园医疗健康(02373)跑赢行业评级 上调目标价至40港元
智通财经网· 2025-08-28 03:17
Core Viewpoint - Company maintains profit forecasts for 2025-2026, with a target price increase of 8% to HKD 40, indicating a 21% upside potential based on strong business model advantages and growth opportunities [1] Financial Performance - Company reported 1H25 revenue of RMB 1.46 billion, a year-on-year increase of 28.2%; net profit attributable to shareholders reached RMB 160 million, up 34.9%; adjusted net profit was RMB 190 million, reflecting a 37.8% increase, exceeding previous forecasts and expectations due to scale effects and operational efficiency [2] Business Segments - Beauty and wellness services generated RMB 810 million in revenue, a 29.6% increase, with direct store traffic up 48.6% to 850,000 and active membership rising 45.7% to 112,000; medical beauty services revenue was RMB 500 million, up 13.0%, with active members increasing 27.6% to 24,000; sub-health medical services revenue surged 107.8% to RMB 150 million, now accounting for over 10% of total revenue, with active members growing 93.4% to 7,014 [3] - The company expanded its store network, adding 69 direct/franchise beauty and wellness stores to reach 238/276, 3 medical beauty stores to total 27, and 2 sub-health stores to 11 [3] Profitability and Efficiency - Gross margin improved by 2.4 percentage points year-on-year to 49.3%, driven by scale effects that reduced procurement costs and diluted fixed costs; adjusted net profit margin reached a historical high of 13.1%, up 0.9 percentage points year-on-year [4] Growth Outlook - The company is focused on enhancing single-store operational efficiency and increasing value-added service penetration while exploring acquisition opportunities to boost market share; recent shareholder structure optimization is expected to support long-term quality growth [5]
美丽田园20250827
2025-08-27 15:19
Summary of the Conference Call for Meili Tianyuan Company Overview - **Company**: Meili Tianyuan - **Industry**: Beauty and Health Services Key Financial Metrics - Adjusted net profit margin reached **13.1%**, a historical high [2] - Operating cash flow increased by **84%** to **¥410 million** [2] - Cash and cash equivalents grew by **28%** to **¥2 billion** [2] - Revenue for the first half of 2025 was **¥1.46 billion**, a **28.2%** year-on-year increase [3] Business Segment Performance - **Lifestyle Beauty and Health**: Revenue of **¥810 million**, up **30%**; active membership increased by **46%** to **112,000** [2][4] - **Medical Aesthetics**: Revenue of **¥500 million**, a **13%** increase; active medical beauty membership rose by **28%** to **24,000** [5] - **Sub-health Medical Services**: Revenue doubled to **¥154 million**, accounting for over **10%** of total revenue [5] Market Dynamics - **Super First-tier Cities**: Contributed **60%** of total revenue, with a growth rate exceeding **50%** in the first half of 2025; pre-tax profit margin reached **25%** [6] - Four core cities achieved single-store revenue exceeding **¥100 million** [6] Acquisition and Integration - **Nairui Integration**: Post-acquisition revenue of **¥277 million**; adjusted net profit margin improved from **6%** to **10.5%** [7] - Annualized revenue per store increased from **¥5.8 million** to **¥7.2 million** [7] Future Growth Strategy - **Revenue Growth Target**: Full-year revenue expected to maintain strong growth, with adjusted net profit projected to increase by **30%** year-on-year [8] - **Expansion Plans**: Focus on both organic growth and acquisitions, targeting leading lifestyle beauty institutions and regional leaders [12] Digital Transformation - Nairui upgraded its digital capabilities from **Smart Beauty 1.0 to 2.0**, enhancing customer experience through a closed-loop model of detection, conditioning, and re-detection [9][10] - Revenue from mini-program distribution reached **¥50 million** in the first half of 2025 [10] Operational Efficiency - Overall gross margin improved from **47%** to **49.3%** [19] - The company aims to enhance operational efficiency through supply chain optimization and increased penetration of value-added services [18] Market Positioning - The company is focused on high-potential markets, particularly in super first-tier cities, to maximize operational efficiency and brand influence [14] - Plans to penetrate new first-tier cities with significant growth potential [16] Customer Engagement - Customer traffic increased by over **45%** in 2025, with same-store sales growth exceeding **5%** [28] - Average customer visits per month are **6**, with semi-annual spending around **¥12,000 to ¥13,000** [28] Conclusion - Meili Tianyuan is positioned for robust growth in the beauty and health services sector, leveraging strategic acquisitions, digital transformation, and operational efficiencies to enhance profitability and market share. The company is optimistic about achieving its ambitious revenue and profit targets for the remainder of 2025 and beyond.
美丽田园医疗健康涨超5%破顶 中期纯利同比增近35% 亚健康管理服务增长强劲
Zhi Tong Cai Jing· 2025-08-27 03:51
Core Viewpoint - Meili Tianyuan Medical Health (02373) saw its stock price rise over 5%, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, a year-on-year increase of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, reflecting a year-on-year growth of 34.9% [1] - Basic earnings per share were reported at 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, up 29.6% year-on-year [1] - Revenue from sub-health medical services reached 150 million RMB, showing a significant increase of 107.8% year-on-year [1] Market Position and Strategy - Huatai Securities highlighted that the company's evolving "dual beauty + dual health" business model is expected to benefit from the rising consumer awareness among women regarding self-care [1] - Since 2025, several Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are anticipated to enhance the product offerings of leading downstream institutions [1] - The firm maintains a buy rating on the stock, reflecting confidence in the company's growth trajectory [1]